AI in Market Access and Pricing

AI payer intelligence in biotech: how to stop guessing what reimbursement bodies want

AI payer intelligence in biotech: how to stop guessing what reimbursement bodies want Most biotech market access strategies are built on past HTA decisions and consultant intuition. That is a fragile foundation when payer bodies are changing their evidence requirements faster than most teams can track. In 2025, the pace of regulatory and reimbursement guidance […]

AI payer intelligence in biotech: how to stop guessing what reimbursement bodies want Read More »

AI Price Corridor Modeling: Stop Leaving Money on the Table at Launch

The MFN executive order and IRA have made pharma pricing a dynamic multi-market corridor management challenge. AI price corridor models continuously track IRP linkages, HTA outcomes, and launch sequence implications across markets. This article explains how biotech market access teams can build AI corridor modeling capability using publicly available data.